DEVELOPMENT OF ORALLY DISINTEGRATING TABLETS OF MEMANTINE HYDROCHLORIDE-A REMEDY FOR ALZHEIMER’S DISEASE

  • IMRAN S. GHOGARI Pacific Academy of Higher Education and Research University, Udaipur, India
  • PRITAM S. JAIN Associate Professor, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India

Abstract

Objective: The study is directed towards the development of an orally disintegrating drug delivery system of memantine hydrochloride which can be commercially exploited for the well-being of society for the treatment of Alzheimer’s disease, which is a most common form of dementia.


Methods: Orally disintegrating immediate-release tablets of memantine hydrochloride were prepared and optimized for disintegration time and in vitro drug release. The top spray granulation method was used for the preparation of granules. Subsequently, these granules were compressed to tablets. The levels of diluent, disintegrant and taste-masking agents were optimized using the design of experiments. The resulting tablets were evaluated for disintegration time and in vitro drug release. The optimized formulation was subjected to accelerated stability study for 3 mo.


Results: The optimized orally disintegrating tablet formulation exhibited a disintegration time of 2-3 min and complete drug release i.e. more than 85 % drug release within 10 min while performing in vitro drug release study. This is a prerequisite for faster action in the case of patients suffering from Alzheimer’s disease. Accelerated stability studies indicated good physical and chemical stability of the optimized formulation.


Conclusion: Developed orally disintegrating tablet formulation of memantine hydrochloride could release the drug faster compared to conventional immediate-release tablets which is useful in paediatric, geriatric and psychiatric patients.

Keywords: Memantine, Orally-disintegrating, Tablets, Super-disintegrants, Alzheimer’s disease, Top-spray

References

1. International statistical classification of diseases and related health problems. 10th Revision. Geneva, World Health Organization; 1992.
2. Chandan R, Shyamal KD. Role of moringaoleifera on brain electrical activity in colchicine induced experimental rat model of Alzheimer’s disease: possible involvement of antioxidants. Int J Curr Pharm Res 2013;5:40-5.
3. The global burden of disease: 2004 update. Geneva, World Health Organization; 2008.
4. World Alzheimer’s Report 2009. London, Alzheimer’s disease International; 2009.
5. Alzheimer Society of Canada. Alzheimer’s disease statistics; 2006. Available from: http://www.alzheimer.ca/english/disease/stats-people.htm. [Last accessed on 25 Jun 2019].
6. Alzheimer Society of Canada. 10 million aging baby boomers heading straight Into Alzheimer's years. Available from: http://www.alzheimer.ca/english/disease/articles-boomers.htm. [Last accessed on 25 Jun 2019]
7. Alzheimer Society of Canada. Alzheimer’s disease: Causes of Alzheimer’s disease; 2005. Available from: http://www.alzheimer.ca/english/disease/causes-intro.htm. [Last accessed on 25 Jun 2019]
8. Ravi G, Gupta NV. Development and evaluation of transdermal film containing solid lipid nanoparticles of rivastigmine tartrate. Int J Appl Pharm 2017;9:85-90.
9. Alzheimer Society of Canada. Shared Experiences: Suggestions for those with Alzheimer's disease. Available from: http://www.alzheimer.ca/docs/brochure-shared-experiences-eng.pdf. [Last accessed on 25 Jun 2019]
10. Alzheimer Society of Canada. Ethical guidelines. Genetic testing; 2005. Available from: http://www.alzheimer.ca/english/care/ethics-genetictest.htm. [Last accessed on 25 Jun 2019]
11. World Population Ageing. New York, United Nations; 2009. Available from: http://www.un.org/esa/population/ publications/WPA2009/WPA2009. [Last accessed on 25 Jun 2019]
12. Preethi B, Vinyaga MP. A review on Alzheimer’s disease: pathology, molecular conditions, management, and causes. Asian J Pharm Clin Res 2017;10:27-30.
13. Abhinav A, Neha S, Navneet K. Prediction of activity spectra of substances assisted prediction of biological activity spectra of potential anti-Alzheimer’s phytoconstituents. Asian J Pharm Clin Res 2017;10Suppl:13.
14. World Alzheimer’s Report: The global economic impact of dementia. London, Alzheimer’s disease International; 2010.
15. Mobius HJ, Stoffler A, Graham SM. Memantine hydrochloride: the pharmacological and clinical profile. Drugs Today 2004;40:685-95.
16. Jagathi V, Anupama B, Praveen PS, Rao GD. Spectrophotometric determination of memantine in bulk and in pharmaceutical formulations. Int J Curr Pharm Res 2010;2:17-8.
17. Jeevitha M, Pandey VP. Formulation and development of orodispersible tablet of memantine hydrochloride. Int J Drug Dev Res 2016;8:38-40.
18. Amin AF, Shah TJ, Bhadani MN, Patel MM. Emerging trends in the development of orally disintegrating tablet technology. Indo Am J Pharm Res 2012;3:221.
Statistics
123 Views | 83 Downloads
Citatons
How to Cite
GHOGARI, I. S., & JAIN, P. S. (2019). DEVELOPMENT OF ORALLY DISINTEGRATING TABLETS OF MEMANTINE HYDROCHLORIDE-A REMEDY FOR ALZHEIMER’S DISEASE. International Journal of Applied Pharmaceutics, 12(1), 147-152. https://doi.org/10.22159/ijap.2020v12i1.36535
Section
Original Article(s)